Business Context and Reporting Period
Mereo Biopharma Group Plc, a clinical-stage UK-based biopharmaceutical company focused on rare diseases, filed this Form 6-K on May 3, 2019. The filing serves as a notification of director dealing in accordance with the EU Market Abuse Regulation.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. It reports solely on a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Purchase |
| Instrument | American Depositary Shares (ADSs) |
| Volume | 3,500 ADSs |
| Aggregated Price | USD 5.077 per share |
| Transaction Date | May 1, 2019 |
| Place of Transaction | XNMS (London Stock Exchange) |
Material Changes
The filing reports a single transaction where John Richard, Head of Corporate Development, purchased 3,500 ADSs. No material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure of an insider trade.
Key Facts for Investor Verification
- Verify the identity of the purchaser: John Richard, Head of Corporate Development.
- Confirm the transaction date of May 1, 2019, and the execution venue (XNMS).
- Note that the purchase price ranged between USD 5.05 and USD 5.09, with an aggregated average of USD 5.077.
- Recognize that this filing does not provide updated financial performance data for the company.